In vivo disposition and metabolism by liver and enterocyte microsomes of the antitubercular drug rifabutin in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 279, Issue 3, 1996, Pages 1300-1309

  Koudriakova, Tatiana ^a,c   Iatsimirskaia, Eugenia ^a   Tulebaev, Samir ^a   Spetie, Dan ^a   Utkin, Ilya ^a   Mullet, Daniel ^a   Thompson, Toni ^b   Vouros, Paul ^b   Gerber, Nicholas ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; RIFABUTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILE FLOW; CONTROLLED STUDY; DRUG BILE LEVEL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG TRANSFORMATION; DRUG URINE LEVEL; FIRST PASS EFFECT; INTESTINE CELL; INTRAVENOUS DRUG ADMINISTRATION; LIVER MICROSOME; MALE; MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RAT; STOMACH JUICE;

ADMINISTRATION, ORAL; ANIMALS; ANTITUBERCULAR AGENTS; BLOOD PROTEINS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FECES; GASTRIC JUICE; INJECTIONS, INTRAVENOUS; INTESTINES; MALE; MICROSOMES; MICROSOMES, LIVER; RATS; RATS, SPRAGUE-DAWLEY; RIFABUTIN; TISSUE DISTRIBUTION;

EID: 0030425312     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. ACOCELLA, G., SERGE, G., CONTI, R., PAGANI, V., PALLANZA, R., PERNA, G. AND SIMONE, P.: Pharmacokinetic study on intravenous rifampicin in man. Pharmacol. Res. Commun. 16: 723-736, 1984.
2. ALBERS, R. AND ROSENBERG, D. M.: In vivo intestinal metabolism of 7-ethoxycoumarin in the rat: Production and distribution of phase I and II metabolites in the isolated, perfused intestinal loop. Toxicol. Appl. Pharmacol. 109: 507-513, 1991.
3. 14C-rifabutin in animals and man. J. Antimicrob. Chemother. 26: 813-822, 1990.
4. 14C-rifabutin in rats. Antimicrob. Agents Chemother. 35: 1391-1396, 1991.
5. BONKOVSKY, H.-L., HAURI, H. P., MARTI, U., GASSER, R. AND MEYER, U. A.: Cytochrome P-450 of small intestinal epithelial cells. Gastroenterology 88: 458-467, 1985.
6. BUSH, M. T. AND DENSEN, P. M.: Systematic multiple fractional extraction procedures. Anal. Chem. 20: 121-129, 1948.
7. COCCHIARA, G., STROLIN BENEDETTI, M., VICARIO, G. P., BALLABIO, M., GIOIA, B., VIOGLIO, S. AND VIGEVANI, A.: Urinary metabolites of rifabutin, a new anti-mycobacterial agent, in human volunteers. Xenobiotica 19: 769-780, 1989.
8. CYNAMON, M. H.: Comparative in vitro activities of MDL 473, rifampicin, and ansamycin against Mycobacterium intracellulare. Antimicrob. Agents Chemother. 28: 440-441, 1985.
9. DELLA BRUNA, C., SCHIOPPACASSI, G., UNGHERI, D., JABES, D., MORVILLO, E. AND SANFILIPPO, A.: LM 427, a new spiropiperidylrifamycin: In vitro and in vivo studies. J. Antibiot. (Tokyo) 36: 1502-1506, 1983.
10. FONTANA, E., GIARDA, S., VIOGLIO, S. AND VICARIO, G. P.: Synthesis of carbon-14 labelled spiro-piperidyl-rifamycins (LM 118) and rifabutin (LM 427). J. Labeled Compounds Radiopharm. 24: 1337-1349, 1987.
11. GONZALEZ, F. J., SONG, B. J. AND HARDWICK, J. P.: Pregnenolone 16α-carbonitrile-inducible P-450 gene family: Gene conversion and differential regulation. Mol. Cell. Biol. 6: 2969-2976, 1986.
12. GUPTA, S. K., BAKRAN, A., JOHNSON, R. W. AND ROWLAND, M.: Cyclosporine-erythromycin interaction in renal transplant patients. Br. J. Clin. Pharmacol. 27: 475-481, 1989.
13. KAMIMURA, H., KOGA, N., OGURI, K. AND YOSHIMURA, H.: Enhanced elimination of theophylline, phenobarbital and strychnine from the bodies of rats and mice by squalane treatment. J. Pharmacobio-Dyn. 15: 215-221, 1992.
14. KOLARS, J. C., STETSON, P. L., RUSH, B. D., RUWART, M. J., SCHMIEDLIN-REN, P., DUELL, E. A., VOORHEES, J. J. AND WATKINS, P. B.: Cyclosporine metabolism by P450IIIA in rat enterocytes: Another determinant of oral bioavailability? Transplantation 53: 596-602, 1992.
15. LENNERNAS, H. AND REGARDH, C.-G.: Dose-dependent intestinal absorption and significant intestinal excretion (exsorption) of the β-blocker pafenolol in the rat. Pharm. Res. 10: 727-732, 1993.
16. LEWIS, R. C., HATFIELD, N. Z. AND NARANG, P. K.: A sensitive method for quantitation of rifabutin and its desacetyl metabolite in human biological fluids by high-performance liquid chromatography (HPLC). Pharm. Res. 8: 1434-1440, 1991.
17. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. AND RANDALL, R. J.: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275, 1951.
18. MARSILI, L., PASQUALUCCI, C. R., VIGEVANI, A., GIOIA, B., SCHIOPPACASSI, G. AND ORONZO, G.: New rifamycins modified at position 3 and 4: Synthesis, structure and biological evaluation. J. Antibiot. (Tokyo) 34: 1033-1038, 1981.
19. MIYAZAKI, H., NAMBU, K. AND HASHIMOTO, M.: Loperamide in rat intestines: A unique disposition. Life Sci. 30: 2203-2206, 1982.
20. NARANG, P. K., LEWIS, R. C. AND BIANCHINE, J. R.: Rifabutin absorption in humans: Relative bioavailability and food effect. Clin. Pharmacol. Ther. 52: 335-341, 1992.
21. NARANG, P. K., TRAPNELL, C. B., SCHOENFELDER, J. R., LAVELLE, J. AND BIANCHINE, J. R.: Fluconazole and enhanced effect of rifabutin prophylaxis. N. Engl. J. Med. 330: 1316-1317, 1994.
22. NASH, D. R., STEELE, L. C., MURPHY, D. AND WALLACE, R. J.: Comparison of drug susceptibility of isolates of Mycobacterium avium complex from AIDS and non-AIDS patients by broth microdilution (Abstract). Am. Rev. Respir. Dis. 137: 261, 1988.
23. OMURA, T. AND SATO, R.: The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 239: 2370-2378, 1964.
24. RAVIGLIONE, M. C., SNIDER, D. E. AND KOCHI, A.: Global epidemiology of tuberculosis. J. Am. Med. Assoc. 273: 220-226, 1995.
25. SARAN, B. R., MAGUIRE, A. M., NICHOLS, C., FRANK, I., HERTLE, R. W., BRUCKER, A. J., GOLDMAN, S., BROWN, M. AND VAN UITERT, B.: Hypopyon uveitis in patients with acquired immunodeficiency syndrome treated for systemic Mycobacterium avium complex infection with rifabutin. Arch. Ophthalmol. 112: 1159-1165, 1994.
26. SKINNER, M. H., HSIEH, M., TORSETH, J., PAULOIN, D., BHATIA, G., HARKONEN, S., MERIGAN, T. C. AND BLASCHKE, T. F.: Pharmacokinetics of rifabutin. Antimicrob. Agents Chemother. 33: 1237-1241, 1989.
27. STROLIN BENEDETTI, M., EFTHYMIOPOULOS, C., SASSELLA, D., MORO, E. AND REPETTO, M.: Autoinduction of rifabutin metabolism in man. Xenobiotica 20: 1113-1119, 1990.
28. TRAPNELL, C. B., NARANG, P. K, LI, R., LEWIS, R., COLBORN, D. AND LAVELLE, J.: Fluconazole (FLU) increases rifabutin (RIF) absorption in HIV(+) patients on stable zidovudine (ZDV) therapy. 9th International Conference on AIDS, June 6-11, 1993. Berlin, Germany (Abstract).
29. TSENG, A. L. AND WALMSLEY, S. L: Rifabutin-associated uveitis. Ann. Pharmacother. 29: 1149-1155, 1995.
30. VIGEVANI, A., BALLABIO, M., GIOIA, B., MARSILI, L., VIOGLIO, S. AND FRANCESCHI, G.: Identification of urinary metabolites of rifamycin LM 427 in man. J. Antibiot. (Tokyo) 38: 1799-1802, 1985.
31. WEISER, M. M.: Intestinal epithelial cell surface membrane glycoprotein synthesis. J. Biol. Chem. 248: 2536-2541, 1973.
32. WOODLEY, C. L. AND KILBURN, J. O.: In vitro susceptibility of Mycobacterium avium complex and Mycobacterium tuberculosis strains to a spiro-piperidyl rifamycin. Am. Rev. Respir. Dis. 126: 586-587, 1982.
33. ZHANG, Q.-Y., WIKOFF, J., DUNBAR, D. AND KAMINSKY, L.: Characterization of rat small intestinal cytochrome P450 composition and inducibility. Drug Metab. Dispos. 24: 322-328, 1996.